DPP-4 Inhibitor Sitagliptin Improves Cardiac Function and Glucose Homeostasis and Ameliorates β-Cell Dysfunction Together with Reducing S6K1 Activation and IRS-1 and IRS-2 Degradation in Obesity Female Mice

Table 1

Baseline and posttreatment parameters of body weight and plasma metabolic markers in control and WD group mice with or without SIT treatment. Values are mean ± SE. compared to the CD or CD + SIT group; compared to the WD group. Sample sizes are noted in parentheses.

Parameter	CD (12)	CD + SIT (12)	WD (12)	WD + SIT (12)
Pretreatment body weight (g)	18.1 ± 0.3	18.2 ± 0.4	18.1 ± 0.3	18.1 ± 0.4
Posttreatment body weight (g)	28.3 ± 1.3	28.8 ± 1.5	51.6 ± 2.5	44.5 ± 2.6^,§
Hepatic weight (mg)	826 ± 32	819 ± 39	2453 ± 196	2232 ± 188
Hepatic triglycerides (nmol/g)	15 ± 3	16 ± 3	45 ± 4	32 ± 4^,§
Plasma cholesterol (mg/dL)	82 ± 5	80 ± 6	157 ± 6	132 ± 8
Plasma triglycerides (mg/dL)	133 ± 10	137 ± 11	325 ± 16	269 ± 18^,§
Plasma alanine aminotransferase (U/L)	25 ± 2	27 ± 3	82 ± 6	63 ± 5^,§